Project Grant R21AG101719
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85257, USA
Similar Awards
- The National Institute on Aging awarded Rensselaer Polytechnic Institute $698,712 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate apolipoprotein E and reelin interactions in Alzheimer's disease pathology. The research tests the hypothesis that APOE E4 competes with reelin for receptor and heparan sulfate binding, thereby reducing protective reelin signaling and increasing Alzheimer's disease risk. Work includes mechanistic studies using split luciferase assays...
- The National Institute on Aging awarded Arizona State University $655,917 under the Aging Research program (CFDA 93.866) on August 15, 2026, to develop and validate deep learning methods that enhance retinal color fundus photography image quality, automate retinal biomarker identification for Alzheimer's disease pathology, and enable scalable, cost-effective preclinical AD risk assessment. The project will create an unsupervised method using optimal transport-guided generative adversarial...
- The National Institute on Aging awarded Arizona State University $675,329 on May 1, 2026, under the Aging Research program (CFDA 93.866) to characterize cellular pathology and biomarkers in an Alzheimer's disease model developed through gene delivery in aged macaque monkeys. The research extends prior work conducted under a companion R24 grant in which the investigators developed a tauopathy model by injecting an adeno-associated virus carrying an aggregation-prone human tau variant...
- The National Institute on Aging awarded Colorado State University $808,980 under the Aging Research program (CFDA 93.866) on September 1, 2026, to develop quantile-focused statistical tools and multimodal analyses that identify nonlinear genetic variants and interactions shaping Alzheimer's disease risk and cellular pathogenesis across key brain cell states. The project will create a comprehensive, distribution-aware genetic architecture atlas and deliver four primary products: quantile-specific...
- The National Institute on Aging awarded Arizona State University $484,575 on September 1, 2026, under the Aging Research program (CFDA 93.866) to evaluate the impact of dietary choline on cognitive decline and Alzheimer's disease biomarkers in rural populations, particularly in Arizona where AD incidence is elevated and elder adults in geographically isolated communities face significantly higher risks of cognitive decline yet remain drastically understudied. The project will investigate...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $454,937 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the regulatory landscape of neurodegeneration using single-cell spatial multiomics approaches. The research integrates chromatin accessibility and protein-level measurements to characterize how cells near Alzheimer's disease hallmarks—amyloid-beta and tau—regulate...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of semaphorin 3A in microglial activation and Alzheimer's disease pathology. The research will determine the functional role and mechanistic basis for semaphorin 3A–mediated regulation of microglial activation in Alzheimer's disease. Building on preliminary findings using human induced pluripotent...
- The National Institute on Aging awarded the University of Arizona $616,013 on September 4, 2026, under the Aging Research program (CFDA 93.866) to conduct a Project Grant testing whether enhancing MET receptor tyrosine kinase signaling can rescue synaptic loss and reverse cognitive decline in an Alzheimer's disease mouse model. The research investigates the central hypothesis that synaptic degeneration in Alzheimer's disease can be mitigated by reactivating MET signaling in the adult brain....
- The National Institute on Aging awarded Boston University Medical Campus $110,228 in project grant funding on February 7, 2027, to develop and validate a novel cellular model of entorhinal cortex layer II vulnerability in Alzheimer's disease under the Aging Research program (CFDA 93.866). The project will develop in vitro models using induced pluripotent stem cells (iPSCs) and direct fibroblast conversion to generate entorhinal cortex layer II (ECII)-like neurons for studying Alzheimer's disease...